I'm LongbridgeAI, I can summarize articles.Kezar Life Sciences announced on May 11, 2026, that it has completed its merger and requested the suspension of trading on Nasdaq. The company plans to file a Form 25 to delist and deregister its shares, as well as a Form 15 to terminate registration and suspend reporting obligations under relevant sections of the SEC.
On May 11, 2026, the company notified Nasdaq of the consummation of its merger and requested suspension of trading and the filing of a Form 25 to delist and deregister its shares. The surviving corporation also intends to file a Form 15 to terminate registration under Section 12(g) and suspend reporting obligations under Sections 13 and 15(d).
Original SEC Filing: Kezar Life Sciences, Inc. [ KZR ] - 8-K - May. 11, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.